Pfizer has developed an interesting technical setup: the stock is currently holding above a gap around $23.50, and a breakout above $26.50 could pave the way toward the $27.69 resistance level. With a stop‑loss placed at $23.58, this trade presents a strong risk‑to‑reward ratio.
From a fundamental perspective, Pfizer deserves attention for its ~7% dividend yield—sitting near the top among S&P 500 healthcare peers—which provides income while investors hold for longer‑term upside.
Though the short‑term target is $27.69, I view Pfizer as a long‑term hold with potential upside beyond the near‑term target, especially given dividend compounding and healthcare industry tailwinds.
https://www.tradingview.com/x/fY0lnN6K/
From a fundamental perspective, Pfizer deserves attention for its ~7% dividend yield—sitting near the top among S&P 500 healthcare peers—which provides income while investors hold for longer‑term upside.
Though the short‑term target is $27.69, I view Pfizer as a long‑term hold with potential upside beyond the near‑term target, especially given dividend compounding and healthcare industry tailwinds.
https://www.tradingview.com/x/fY0lnN6K/
Penafian
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Penafian
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.